iSpecimen Stock to Reverse Split on Tuesday, April 28th (NASDAQ:ISPC)

iSpecimen Inc. (NASDAQ:ISPC)’s stock is going to reverse split before the market opens on Tuesday, April 28th. The 1-40 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

iSpecimen Price Performance

Shares of ISPC stock traded down $0.03 during trading on Friday, reaching $0.13. The company’s stock had a trading volume of 27,448,865 shares, compared to its average volume of 22,726,467. The company has a market capitalization of $3.87 million, a price-to-earnings ratio of -0.06 and a beta of 1.98. The stock’s 50-day moving average price is $0.20 and its 200 day moving average price is $0.40. iSpecimen has a 1-year low of $0.10 and a 1-year high of $3.18.

iSpecimen (NASDAQ:ISPC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.74) earnings per share for the quarter. iSpecimen had a negative net margin of 543.37% and a negative return on equity of 496.31%. The business had revenue of $0.05 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a report on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Trading of iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Virtu Financial LLC acquired a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned approximately 0.65% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is owned by institutional investors and hedge funds.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.